Common Contracts
3 similar License Agreement contracts by Adamas Pharmaceuticals Inc
Amendment date: Jan 09 2015License Agreement • November 21st, 2021 • New York
Adamas Pharmaceuticals has received a $25 million milestone payment from Forest Laboratories related to the development of MDX-8704.
LICENSE AGREEMENT BY AND BETWEEN FOREST LABORATORIES HOLDINGS LIMITED AND ADAMAS PHARMACEUTICALS, INC. DATED AS OF NOVEMBER 13, 2012License Agreement • March 5th, 2014 • Adamas Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT is entered into this 13th day of November, 2012 (the “Effective Date”), by and between Forest Laboratories Holdings Limited, a corporation organized under the laws of the Republic of Ireland, having a business address at Cumberland House, 9th Floor, 1 Victoria Street, Hamilton HM11, Bermuda (“Forest”), an indirect, wholly owned subsidiary of Forest Laboratories, Inc. (“Forest Parent”), and Adamas Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 2200 Powell Street, Suite 220, Emeryville, California 94608 (“Adamas”).
LICENSE AGREEMENT BY AND BETWEEN FOREST LABORATORIES HOLDINGS LIMITED AND ADAMAS PHARMACEUTICALS, INC. DATED AS OF NOVEMBER 13, 2012License Agreement • January 31st, 2014 • Adamas Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT is entered into this 13th day of November, 2012 (the “Effective Date”), by and between Forest Laboratories Holdings Limited, a corporation organized under the laws of the Republic of Ireland, having a business address at Cumberland House, 9th Floor, 1 Victoria Street, Hamilton HM11, Bermuda (“Forest”), an indirect, wholly owned subsidiary of Forest Laboratories, Inc. (“Forest Parent”), and Adamas Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 2200 Powell Street, Suite 220, Emeryville, California 94608 (“Adamas”).
